Total submissions: 3
| Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
|---|---|---|---|---|---|---|---|---|
| Invitae | RCV000646200 | SCV000767959 | uncertain significance | Brugada syndrome 4 | 2023-08-30 | criteria provided, single submitter | clinical testing | This sequence change replaces arginine, which is basic and polar, with cysteine, which is neutral and slightly polar, at codon 554 of the CACNB2 protein (p.Arg554Cys). This variant is present in population databases (no rsID available, gnomAD 0.005%). This variant has not been reported in the literature in individuals affected with CACNB2-related conditions. ClinVar contains an entry for this variant (Variation ID: 537367). An algorithm developed to predict the effect of missense changes on protein structure and function (PolyPhen-2) suggests that this variant is likely to be disruptive. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |
| Ambry Genetics | RCV002397258 | SCV002707532 | uncertain significance | Cardiovascular phenotype | 2022-11-19 | criteria provided, single submitter | clinical testing | The p.R554C variant (also known as c.1660C>T), located in coding exon 13 of the CACNB2 gene, results from a C to T substitution at nucleotide position 1660. The arginine at codon 554 is replaced by cysteine, an amino acid with highly dissimilar properties. This amino acid position is well conserved in available vertebrate species. In addition, the in silico prediction for this alteration is inconclusive. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. |
| Fulgent Genetics, |
RCV000646200 | SCV002776533 | uncertain significance | Brugada syndrome 4 | 2021-11-20 | criteria provided, single submitter | clinical testing |